Siemens Healthineers AG said Thursday that its first-quarter revenue and earnings rose, and upgraded its guidance for fiscal 2022 as it expects to generate more revenue from its rapid Covid-19 antigen tests.
The German medical-equipment maker said net income was 472 million euros ($533.6 million) in the quarter ended Dec. 31 up from EUR437 million a year earlier.
Revenue was EUR5.07 billion, up 9.5% on year on a comparable basis, the company said. Analysts had expected the company to post quarterly revenue of EUR4.93 billion, according to a FactSet consensus.
Excluding rapid Covid-19 antigen tests, revenue rose 4.5%.
Siemens Healthineers said it now expects the tests to generate around EUR700 million in revenue, compared with previous expectations of EUR200 million, in fiscal 2022.
As a result, it raised its annual comparable revenue growth guidance to 3% to 5%, from 0%-2% previously, and its targeted adjusted basic earnings per share to EUR2.18-EUR2.30, from EUR2.08-EUR2.20 previously.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.